AUA 2017 Annual Meeting Neoadjuvant Chemo Benefits Some Variant MIBC Patients

Neoadjuvant Chemo Benefits Some Variant MIBC Patients

Researchers find prolonged survival among patients with neuroendocrine muscle-invasive bladder cancer.

AUA 2017 Annual Meeting Post-chemo PD-L1 Tied to Worse Prognosis in Bladder Cancer Pts

Post-chemo PD-L1 Tied to Worse Prognosis in Bladder Cancer Pts

Five-year cancer-specific survival rates were 48.1% and 69.6% for PD-L1 positive and negative patients, respectively.

AUA 2017 Annual Meeting AUA Releases Updated Renal Mass Guidelines

AUA Releases Updated Renal Mass Guidelines

The document spells out in greater detail the criteria for radical and partial nephrectomy and for placing patients on active surveillance.

AUA 2017 Annual Meeting PCa Active Surveillance Safe, Effective for Younger Patients

PCa Active Surveillance Safe, Effective for Younger Patients

A majority of active surveillance patients under age 60 did not progress to definitive prostate cancer treatment.

AUA 2017 Annual Meeting MRI-Fusion Biopsy Benefits PCa Active Surveillance Patients

MRI-Fusion Biopsy Benefits PCa Active Surveillance Patients

Targeting PI-RADS 4 and 5 lesions for confirmatory biopsy improves detection of clinically significant cancer.

AUA 2017 Annual Meeting Sipuleucel-T Survival Benefit Greater in Blacks

Sipuleucel-T Survival Benefit Greater in Blacks

Median overall survival was 9.3 months longer for black versus white patients with metastatic castration-resistant prostate cancer.

AUA 2017 Annual Meeting Low Testosterone Increases Women's Urinary Incontinence Risk

Low Testosterone Increases Women's Urinary Incontinence Risk

Lowest quartile of serum testosterone is associated with 48% and 65% increased odds of stress and mixed urinary incontinence, respectively.

AUA 2017 Annual Meeting Fusion Biopsy Ups Detection of Clinically Significant PCa

Fusion Biopsy Ups Detection of Clinically Significant PCa

Fusion biopsy has improved over the last decade and increasingly detects clinically significant prostate cancer, according to data trends from one institution.

AUA 2017 Annual Meeting Prostate Photovaporization for BPH Beneficial Long-Term

Prostate Photovaporization for BPH Beneficial Long-Term

Average International Prostate Symptom Score remained low 5 years after the PVP laser procedure.

AUA 2017 Annual Meeting New-Onset Urinary Incontinence Common After HoLEP for BPH

New-Onset Urinary Incontinence Common After HoLEP for BPH

Researchers identified a predictor of new-onset UI after HoLEP that may aid urologists in clinical practice.

AUA 2017 Annual Meeting Water Vapor Ablation Eases BPH-Related Urinary Retention

Water Vapor Ablation Eases BPH-Related Urinary Retention

In a study, 81.1% of men were able to void after an average of 28 days after treatment.

AUA 2017 Annual Meeting Prostate Cancer Distant Metastasis Predicted by APV

Prostate Cancer Distant Metastasis Predicted by APV

Highest quartile of alkaline phosphatase velocity in men who experience biochemical recurrence after radical prostatectomy is associated with 2-fold higher risk.

AUA 2017 Annual Meeting Non-index Lesions at Biopsy Help Predict Adverse RP Outcomes

Non-index Lesions at Biopsy Help Predict Adverse RP Outcomes

Systematic biopsy parameters identified patients at higher risk of positive surgical margins.

AUA 2017 Annual Meeting Bladder Cancer Survival Worse Among Women Despite RC

Bladder Cancer Survival Worse Among Women Despite RC

Among stage 2 to 4 bladder cancer patients, women had lower cancer-specific survival than men.

AUA 2017 Annual Meeting HoLEP Feasible for BPH Patients With Low-risk Prostate Cancer

HoLEP Feasible for BPH Patients With Low-risk Prostate Cancer

The laser procedure was successful for 7 selected patients with enlarged prostates and LUTS harboring low-risk prostate cancer.

AUA 2017 Annual Meeting Variant Histology Predicts Worse Bladder Cancer Outcomes

Variant Histology Predicts Worse Bladder Cancer Outcomes

Study finds a higher death risk following radical cystectomy for squamous cell and small cell carcinoma and micropapillary histologic subtypes.

AUA 2017 Annual Meeting VTE Risk Continues Long After Bladder Cancer Surgery

VTE Risk Continues Long After Bladder Cancer Surgery

The cumulative incidence of venous thromboembolism following radical cystectomy was nearly 6.7% over 10 years.

AUA 2017 Annual Meeting Early CRP Response to mRCC Drugs Predicts Survival

Early CRP Response to mRCC Drugs Predicts Survival

Changes in C-reactive protein levels 4 weeks after starting sunitinib or sorafenib treatment are associated with overall and progression-free survival.

AUA 2017 Annual Meeting Post-Cystectomy Deaths Among HD Patients Seldom Due to Cancer

Post-Cystectomy Deaths Among HD Patients Seldom Due to Cancer

Following radical cystectomy for bladder cancer, end-stage renal disease patients are 3-4 times more likely to die from causes other than cancer.

AUA 2017 Annual Meeting Continent Diversion After Bladder Cancer Surgery on the Decline

Continent Diversion After Bladder Cancer Surgery on the Decline

Use of continent diversion procedures peaked in 2008, and has been decreasing since.

Sign Up for Free e-newsletters